Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 11/20 | 0.48 |
| ▸ | CSNK1E | P49674 | 11/20 | 0.48 |
| ▸ | MAP3K5 | Q99683 | 6/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498826 | 0.95 | HIF1A (0.48) | HIF1AEPAS1CSNK1DCSNK1EMAP3K5 | |
| Trifluoroacetic Acid SCHEMBL3486390 | 0.91 | HIF1A (0.50) | HIF1AEPAS1CSNK1DCSNK1EMAP3K5 | |
| Trifluoroacetic Acid SCHEMBL3486340 | 0.88 | HIF1A (0.46) | HIF1AEPAS1CSNK1DCSNK1EMAP3K5 | |
| Trifluoroacetic Acid SCHEMBL3485446 | 0.87 | GPR6 (0.45) | CSNK1DCSNK1EMAP3K5 | |
| Trifluoroacetic Acid SCHEMBL3486927 | 0.86 | CSNK1D (0.51) | CSNK1DCSNK1EMAP3K5 | |
| SCHEMBL13498825 | 0.85 | MAP3K5 (0.51) | HIF1AEPAS1CSNK1DCSNK1EMAP3K5 | |
| Trifluoroacetic Acid SCHEMBL3486132 | 0.82 | MAP3K5 (0.48) | CSNK1DCSNK1EMAP3K5 | |
| SCHEMBL13498829 | 0.82 | MAP3K5 (0.46) | HIF1AEPAS1CSNK1DCSNK1EMAP3K5 | |
| SCHEMBL13498824 | 0.81 | MAP3K5 (0.48) | CSNK1DCSNK1EMAP3K5 | |
| Trifluoroacetic Acid SCHEMBL3486139 | 0.80 | MAP3K5 (0.46) | CSNK1DCSNK1EMAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257536-A2 | CYCLIC DIARYL ETHER AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| WO-2009102893-A2 | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | HIF1A 900/4885EPAS1 1002/4885CSNK1D 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.